PROGRESSION-FREE SURVIVAL IN ADVANCED CLASSICAL HODGKIN LYMPHOMA PATIENTS WITH BULKY DISEASE AFTER ABVD WITHOUT RADIATION THERAPY IN ERA PET

被引：0
|
作者：
Puccini, B. [1 ]
Rigacci, L. [1 ]
Romano, I. [2 ]
Berti, V. [3 ]
Palazzo, M. [2 ]
Galli, E. [2 ]
Ciolli, G. [2 ]
Merlini, M. [2 ]
Vannucchi-, A. M. [1 ,2 ]
Nassi, L. [1 ]
机构：
[1] Careggi Hosp, Dept Haematol, Lymphoma Unit, Florence, Italy
[2] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[3] Univ Florence, Dept Expt & Clin Biomed Sci, Nucl Med Unit, Florence, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D068
引用
收藏
页码：138 / 139
页数：2
相关论文
共 50 条
  • [21] Rituximab maintenance therapy significantly increases progression-free survival of follicular lymphoma patients
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 6 - 6
  • [22] The significance of a positive PET scan after chemotherapy with ABVD and prior to involved field radiation therapy in Hodgkin's lymphoma
    Ghaloori, A.
    Clough, R.
    Wong, T. Z.
    Prosmiz, L.
    Kelsey, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S471 - S471
  • [23] Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma
    Jorgensen, Rasmus Rask Kragh
    Bergstroem, Fanny
    Eloranta, Sandra
    Severinsen, Marianne Tang
    Smeland, Knut Bjoro
    Fossa, Alexander
    Christensen, Jacob Haaber
    Hutchings, Martin
    Bo Dahl-Sorensen, Rasmus
    Kamper, Peter
    Glimelius, Ingrid
    Smedby, Karin
    Parsons, Susan
    Rodday, Angie Mae
    Maurer, Matthew
    Evens, Andrew
    El-Galaly, Tarec
    Jakobsen, Lasse Hjort
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [24] Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
    McClune, Brian L.
    Ahn, Kwang Woo
    Wang, Hai-Lin
    Antin, Joseph H.
    Artz, Andrew S.
    Cahn, Jean-Yves
    Deol, Abhinav
    Freytes, Cesar O.
    Hamadani, Mehdi
    Holmberg, Leona A.
    Jagasia, Madan H.
    Jakubowski, Ann A.
    Kharfan-Dabaja, Mohamed A.
    Lazarus, Hillard M.
    Miller, Alan M.
    Olsson, Richard
    Pedersen, Tanya L.
    Pidala, Joseph
    Pulsipher, Michael A.
    Rowe, Jacob M.
    Saber, Wael
    van Besien, Koen W.
    Waller, Edmund K.
    Aljurf, Mahmoud D.
    Akpek, Goergun
    Bacher, Ulrike
    Chao, Nelson J.
    Chen, Yi-Bin
    Cooper, Brenda W.
    Dehn, Jason
    de Lima, Marcos J.
    Hsu, Jack W.
    Lewis, Ian D.
    Marks, David I.
    McGuirk, Joseph
    Cairo, Mitchell S.
    Schouten, Harry C.
    Szer, Jeffrey
    Ramanathan, Muthalagu
    Savani, Bipin N.
    Seftel, Matthew
    Socie, Gerard
    Vij, Ravi
    Warlick, Erica D.
    Weisdorf, Daniel J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (07) : 960 - 968
  • [25] Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition
    Hude, Ida
    Sasse, Stephanie
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Momotow, Jesko
    Engert, Andreas
    Borchmann, Sven
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (06) : 837 - 840
  • [26] Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection
    Okosun, Jessica
    Warbey, Victoria
    Shaw, Kate
    Montoto, Silvia
    Fields, Paul
    Marcus, Robert
    Virchis, Andres
    McNamara, Christopher
    Bower, Mark
    Cwynarski, Kate
    AIDS, 2012, 26 (07) : 861 - 865
  • [27] Rituximala plus ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy
    Wedgwood, Amanda R.
    Fanale, Michelle A.
    Fayad, Luis E.
    McLaughlin, Peter
    Flagemeister, Fredrick B.
    Pro, Barbara
    Romaguera, Jorge
    Rodriguez, Maria A.
    Samaniego, Felipe
    Younes, Anas
    BLOOD, 2007, 110 (11) : 71A - 71A
  • [28] Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts
    Ghesquieres, Herve
    Maurer, Matthew J.
    Casasnovas, Olivier
    Ansell, Stephen M.
    Larrabee, Beth R.
    Lech-Maranda, Eva
    Novak, Anne J.
    Borrel, Anne-Laure
    Slager, Susan L.
    Brice, Pauline
    Allmer, Cristine
    Brion, Annie
    Ziesmer, Steven C.
    Morschhauser, Franck
    Habermann, Thomas M.
    Gaillard, Isabelle
    Link, Brian K.
    Stamatoullas, Aspasia
    Ferme, Christophe
    Dogan, Ahmet
    Macon, William R.
    Audouin, Josee
    Cerhan, James R.
    Salles, Gilles
    CYTOKINE, 2013, 64 (02) : 523 - 531
  • [29] Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation
    Savage, Kerry J.
    Connors, Joseph M.
    Villa, Diego R.
    Hapgood, Greg
    Gerrie, Alina S.
    Shenkier, Tamara N.
    Scott, David W.
    Gascoyne, Randy D.
    Benard, Francois
    Morris, James
    Pickles, Tom
    Parsons, Christina
    Wilson, Don
    Sehn, Laurie H.
    BLOOD, 2015, 126 (23)
  • [30] Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients
    Li, Mengyao
    Dave, Nimita
    Salem, Ahmed Hamed
    Freise, Kevin J.
    MEDICINE, 2017, 96 (35)
12345